Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-11-17
pubmed:abstractText
Functional gastrointestinal disorders (FGIDs) are common conditions diagnosed by established symptom-based criteria. Dysregulation of the brain-gut axis is emerging as the primary pathophysiologic mechanism for FGIDs; this opens avenues for newer treatment modalities. Psychotropic agents act on a variety of neurotransmitter receptors in the brain-gut regulatory pathways that target serotonergic, dopaminergic, opioidergic, and noradrenergic receptor sites. The role of psychotropic agents, especially tricyclic antidepressants is fairly well established in the management of FGIDs and benefit from the newer serotonin norepinephrine reuptake inhibitors is promising. Selective serotonin reuptake inhibitors may provide benefit by reducing symptom anxiety and achieve global symptom relief. In spite of expanding research in evaluating these potential agents, there remains an unmet need in pharmacological management of these disorders, especially at the severe end of their spectrum where options for combined treatments or augmentation need to be developed. In addition, the understanding and management of these disorders hinges on a multidisciplinary biopsychosocial approach, which itself can be a challenging strategy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1471-4892
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
715-23
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Psychotropic agents in functional gastrointestinal disorders.
pubmed:affiliation
Department of Internal Medicine, Michigan State University, East Lansing, MI, USA.
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural